RESEARCH TRIANGLE PARK – GSK’s latest quarterly financials include an upgrade in expectations. Those include:

  • Turnover (collections of cash vs. inventory) to increase 12 to 13% (from 8 to 10%)
  • Adjusted operating profit growth 13 to 15% (from 11 to 13%)
  • Adjusted EPS growth 17 to 20% (from 14 to 17%)

“GSK is delivering strong and sustained performance momentum, with another quarter of double-digit sales and
earnings growth,” said CEO Emma Walmsley in a statement.

“Competitive performance was broadly based but benefitted particularly from the outstanding US launch of Arexvy, the world’s first RSV vaccine. Our excellent execution supports an upgrade to our full-year 2023 guidance and we have clear momentum as we look ahead to deliver our 2026 outlooks. GSK’s longer-term outlook also continues to strengthen, with progress in our vaccines pipeline, the development of our ultra long-acting HIV portfolio and significant new prospects in respiratory.”

GSK employs thousands of people across the Triangle and is majority owner of ViiV Healthcare, which has a large operation in RTP.

More GSK news

GSK strikes $1 billion licensing, development deal for potential hepatitis B treatment

GSK signs $20M deal to license genetic data from 23andMe